As Executive Leader and Director of Tijan Ventures/Vigilance Health Pty Ltd, Tim Oldham grows life sciences businesses, particularly in the field of cell and gene therapy and immunotherapy. He provides strategic advice, interim management and executive and board leadership to established and start-up companies.
Previous executive roles span more than 15 years of life sciences business development, alliance management and sales and marketing experience in Europe, Asia and Australia. He has been CEO/MD of Cell Therapies Pty Ltd (manufacturing and distribution services for cell therapeutics), President of Asia Pacific for Hospira Inc. and held various European business development, strategic marketing and regional leadership roles with Mayne Pharma (injectable generics, biosimilars and infusion management systems). After gaining his PhD (Chemistry) at Imperial College, London he was an engagement manager with McKinsey & Company.
Current Non-executive Director roles include Acrux Ltd and Imunexus Ltd and he is a former Non-Executive Director of Respiri Ltd. Other industry advocacy roles include current membership of AusBiotech’s Regenerative Medicine Advisory Group, and past chair of the European Generic Medicines Association’s Biosimilars and Biotechnology Committee, Director of the Generic Medicines Industry Association and the Alliance for Regenerative Medicine.